The Goldman Sachs Group Reaffirms Sell Rating for Intellia Therapeutics (NASDAQ:NTLA)

The Goldman Sachs Group reissued their sell rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Friday, MarketBeat reports. The Goldman Sachs Group currently has a $9.00 price target on the stock.

A number of other analysts also recently issued reports on the company. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday. Canaccord Genuity Group reissued a “buy” rating and issued a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Oppenheimer decreased their target price on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. William Blair reissued a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.12.

Intellia Therapeutics Trading Down 7.1 %

Shares of NTLA opened at $10.09 on Friday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80. The stock has a 50 day moving average of $10.90 and a 200 day moving average of $15.72. Intellia Therapeutics has a 12 month low of $8.96 and a 12 month high of $34.87.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. bought a new stake in Intellia Therapeutics during the fourth quarter valued at $25,000. Sterling Capital Management LLC lifted its stake in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics during the fourth quarter worth about $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics during the fourth quarter worth about $43,000. Finally, Jones Financial Companies Lllp lifted its stake in Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.